1. Home
  2. PRHI vs CVKD Comparison

PRHI vs CVKD Comparison

Compare PRHI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Presurance Holdings Inc.

PRHI

Presurance Holdings Inc.

HOLD

Current Price

$5.25

Market Cap

14.2M

Sector

Finance

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$4.32

Market Cap

15.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRHI
CVKD
Founded
2009
2022
Country
United States
United States
Employees
9
N/A
Industry
Property-Casualty Insurers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2M
15.3M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
PRHI
CVKD
Price
$5.25
$4.32
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
28.5K
56.3K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$4.21
52 Week High
$2.83
$15.99

Technical Indicators

Market Signals
Indicator
PRHI
CVKD
Relative Strength Index (RSI) 95.42 34.30
Support Level $0.60 $4.21
Resistance Level N/A $5.99
Average True Range (ATR) 0.12 0.50
MACD 0.31 -0.07
Stochastic Oscillator 100.00 15.51

Price Performance

Historical Comparison
PRHI
CVKD

About PRHI Presurance Holdings Inc.

Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: